VRTX
Vertex Pharmaceuticals Inc
$528.04+6.03%
Setup
Watch
Buy Zone
$519.21-$545.17
Sector
Biotechnology
Industry
Biotechnology
63
Recommendation
Extended
Watch
Setup may be valid but price is no longer in a clean buy zone.
VRTX chart
Loading chart…
Overall Quality63
RS Rating
48
relative strength
Fundamentals
85
Strong fund-Q
Volume Demand
82
+32% vs avg
Technical Setup
75
6/8 checks
Industry/Theme
91
Biotechnology
Trade Plan
Extended
Entry
$519.21
Entry Zone
$519.21-$545.17
Stop / Risk
$477.67
RS Rating
48
Volume confirmed
Yes
Targets
$623.05 / $649.01
Breakout · IBD Setup
3 ✓ 5 ✗
Entry $519.21–$545.17Stop $477.67Target $623.05 / $649.01
Market regimeRange
Quality63
RS Rating48
Above 50-MA+18.15%
Above 200-MA+18.96%
VolumeConfirmed
In Buy ZoneNo
Not extendedExtended
Invalidation · Close below stop
How this came together
63
MarketRange
SetupWatch
ConfidenceExperimental · not backtested
Fund-Q85 · Strong
StatusWatch
Stock Data
52-Week Range362 – 508
Price % Chg YTD16.47%
Price % Chg 4wk24.22%
50-Day Avg Vol1.4 Mil
P/E Ratio29.1
Market Cap$125B
SectorHealthcare
IndustryBiotechnology
Company Fundamentals
EPS % Chg (Qtr)61.58%
Sales % Chg (Qtr)9.7%
EPS Growth 5y8.28%
Sales Growth 5y14.23%
Annual ROE24.2%
Gross Margin86.38%
Operating Margin39.85%
Net Margin35.15%
Debt / Equity0.10
Setup levels
Current price
$528.04
Pivot
$519.21
Distance to buy
+4%
52-week range
362.49-507.93
Trigger evidence
No active trigger evidence available.
Pattern levels: near highs
Financial health checks
5/5
Return on equity above 15%
ROE 24.2%
Net margin above 10%
Net margin 35.15%
EPS growing quarter on quarter
EPS q/q 61.58%
Sales growing quarter on quarter
Sales q/q 9.7%
Debt to equity below 1.0
D/E 0.10
Key metrics
Finviz snapshot · value vs. sector median (≥5 peers)
Annual ROE24.2%
vs sector +1.2%
Net margin35.15%
vs sector +15.8%
Gross margin86.38%
vs sector +14.7%
EPS growth q/q61.58%
vs sector +42.4%
Sales growth q/q9.7%
vs sector -11.5%
Debt / equity0.10
vs sector -0.62
Business quality
85
GradeStrong
EPS rating71
P/E29.1
Market cap$125B
IndustryBiotechnology
Technical checks
Über 50-MA
Pass
Über 200-MA
Pass
RS-Linie auf neuem Hoch
Pass
Volumen bestätigt
Pass
In Kaufzone
Fail
Nicht überextended
Fail
Über 21-EMA
Pass
Volumen gesund
Pass
IBD / source mentions
No recent IBD mention found for this ticker.
Signal history
Added to list
2026-06-28
Trigger date
—
Days on list
6
Data sources: internal CANSLIM engine · Finviz snapshot · TradingView chart. Not investment advice.